Mode
Home
Conditions Medications Drug Pipeline Weekly Digests
Text Size
Log in / Sign up
Home › Conditions › X-linked hypophosphatemia

X-linked hypophosphatemia

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Crysvita (burosumab) for X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia
Pediatrics FDA Approval
FDA Approves Crysvita (burosumab) for X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia FDA approves new drug Crysvita for rare bone diseases in children and adults.
FDA approved Crysvita (burosumab) for X-linked hypophosphatemia (XLH) in patients 6 months and older and for tumor-induced osteomalacia (TIO…
The FDA approved Crysvita (burosumab) for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). It is the first treatment th…
FDA Apr 29, 2026
Substudy of Phase 3 trials: Nonfasting burosumab phosphorus levels in XLH patients remain stable after meals
Drug Pipeline
Substudy of Phase 3 trials: Nonfasting burosumab phosphorus levels in XLH patients remain stable after meals Burosumab Patients May Skip Fasting Before Blood Tests
This abstract describes a substudy of Phase 3 clinical trials evaluating burosumab in adults and children with X-linked hypophosphatemia. Th…
Imagine rushing your child to a morning blood draw, stomach empty, hungry and fussy—only to find out the results might not even require fast…
Apr 24, 2026